- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
ALLEGAN, Mich. — The Food and Drug Administration has granted market exclusivity for a generic version of a medication designed to treat indoor and outdoor allergies.
Perrigo said Monday that its licensor and supplier Synthon received regulatory approval for levocetirizine tablets, a generic version of UCB/Sepracor's Xyzal, which is marketed in the United States by Sanofi-Aventis.
The levocetirizine tablet is the only approved generic product having a label containing all indications, Perrigo said.